Positive correlation of insulin-like growth factor-II with proliferating cell index in patients with colorectal neoplasia

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 7, 2005, Pages 1819-1822

  Zhao, Ronghua ^a   Berho, Mariana ^a   Nogueras, Juan ^a   Sands, Dana ^a   Weiss, Eric ^a   Wexner, Steven ^a   Giardiello, Francis M ^b   Cruz Correa, Marcia ^a,b  

^a DEPARTMENT OF COLORECTAL SURGERY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; SOMATOMEDIN B;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL PROLIFERATION; COLON POLYP; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

AGED; COLORECTAL NEOPLASMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 22244438837     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-04-0803     Document Type: Article

References (24)

1. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Holly JM, Wass JA. Insulin-like growth factors: autocrine, paracrine or endocrine? New perspectives of the somatomedin hypothesis in the light of recent developments. J Endocrinol 1989;122:611-8.
3. Renehan AG, Jones J, Potten CS, et al. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000;83:1344-50.
4. Renehan AG, Painter JE, O'Halloran D, et al. Circulating insulin-like growth factor II and colorectal adenomas. J Clin Endocrinol Metab 2000; 85:3402-8.
5. Michell NP, Langman MJ, Eggo MC. Insulin-like growth factors and their binding proteins in human colonocytes: preferential degradation of insulin-like growth factor binding protein 2 in colonic cancers. Br J Cancer 1997; 76:60-6.
6. Lambert S, Vivario J, Boniver J, et al. Abnormal expression and structural modification of insulin-like growth factor II gene in human colorectal tumors. Int J Cancer 1990;46:405-10.
7. Tricoli JV, Rall LB, Karakousis CP, et al. Enhanced levels of insulin-like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986;46:6169-73,
8. Kawamoto K, Onodera H, Kondo S, et al. Expression of insulin-like growth factor-2 can predict the prognosis of human colorectal cancer patients: correlation with tumor progression, proliferative activity and survival. Oncology (Basel) 1998;55:242-8.
9. Peter G, Gongoll S, Langner C, et al. IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch 2003;443:139-45.
10. Cadoret A, Baron-Delage S, Bertrand F, et al. Oncogene-induced upregulation of Caco-2 cell proliferation involves IGF-II gene activation through a protein kinase C mediated pathway. Oncogene 1998;17:877-87.
11. Hassan AB, Howell JA. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Epidemiol Biomarkers Prev 2000;9:345-9.
12. Szepeshazi K, Schally AV, Groot K, et al. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 2000;82:1724-31.
13. Hunt KJ, Toniolo P, Akhmedkhanov A, et al. Insulin-like growth factor II and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 2002;11:901-5.
14. Cui H, Onyango P, Brandenburg S, et al. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2. Cancer Res 2002;62: 6442-6.
15. O'Dell SD, Day IN. Insulin-like growth factor II (IGF-II). Int J Biochem Cell Biol 1998;30:767-71.
16. Moschos SJ, Mantzoros CS. The role of the IGF system in the cancer: from basic to clinical studies and clinical applications. Oncology 2002;63: 317-32.
17. Adachi Y, Lee CT, Coffee K, et al. Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines. Gastroenterology 2002;123:1191-204.
18. Kelly RG, Nally K, Shanahan F, et al. Type I insulin-like growth factor receptor expression on colorectal adenocarcinoma cell lines is decreased in response to the chemopreventive agent N-acetyl-L-cysteine. Ann N Y Acad Sci 2002;973:555-8.
19. Freier RJ, Weiss O, Eran M, et al. Expression of insulin-like growth factors and their receptors in adenocarcinoma of colon. Gut 1999;44:704-8.
20. Sohda T, Oka Y, Iwata K, et al. Co-localisation of insulin-like growth factor II and the proliferation marker M1B1 in hepatocellular carcinoma cells. J Clin Pathol 1997;50:135-7.
21. Remacle-Bonnet MM, Culouscou JM, Garrouste FL, et al. Expression of type I, but not type II insulin-like growth factor receptor on both undifferentiated and differentiated HT-29 human colon carcinoma cell line. J Clin Endocrinol Metab 1992;75:609-16.
22. Culouscou JM, Shoyab M. Purification of a colon cancer cell growth inhibitor and its identification as an insulin-like growth factor binding protein. Cancer Res 1991;51:2813-9.
23. Barozzi C, Ravaioli M, D'Errico A, et al. Relevance of biologic markers in colorectal carcinoma: a comparative study of a broad panel. Cancer 2002; 94:647-57.
24. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF-2 imprinting: a potential marker of colorectal cancer risk. Science 2003;299:1753-5.